1. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations.
- Author
-
Dhainaut, F., Guillaumat, P.‐O., Dib, H., Perret, G., Sauger, A., de Coupade, C., Beaudet, M., Elzaabi, M., and Mouthon, L.
- Subjects
IMMUNOGLOBULIN G ,COMPARATIVE studies ,INTRAVENOUS therapy ,COMPLEMENT activation ,LABORATORY rats ,ANTIGENS - Abstract
Objective To compare in vitro and in vivo biological and biochemical properties of five liquid intravenous immunoglobulin (IVIg) preparations licensed for therapeutic use in Europe. Methods ClairYg
® was compared in a blinded manner to four other liquid IVIg preparations licensed in Europe (Octagam® , Kiovig® , Gamunex® , Privigen® ). Three batches of each preparation were tested, except for the IgG repertoires and the animal model. Results Levels of anti-A and anti-B antibodies were lower in ClairYg® (0·11/0·11) relative to a positive EDQM standard and Octagam® (0·11/0·08) than in other preparations (0·33-0·69/0·42-0·46). IgG in ClairYg® recognized 365 and 416 protein spots in HEp-2 cell and Escherichia coli protein extracts vs. 230-330 and 402-842 protein spots, respectively, for IgG in other preparations. IgA content (301 vs. 165-820 ng/mg of IgG), Factor XI and Factor XII antigen (0·46 vs. 0·85-2·40 mU/mg of IgG and 7·8 vs. 20·0-46·2 lU/mg of IgG) C1q binding (0·42 vs. 0·67-1·89 arbitrary units) and C5a uptake (0·41 vs. 0·45-0·66% of activation) were lower in ClairYg® than in other preparations. Finally, intravenous infusion of ClairYg® , Gamunex® and Privigen® had no major effect on arterial blood pressure in spontaneously hypertensive rats. Conclusions Our results evidence some differences in the biological and biochemical properties among licensed liquid IVIg preparations. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF